Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|August 15, 2020
- Ophthalmology Times: July 15, 2020
- Volume 45
- Issue 12
Diagnosing a 'down looker'
Author(s)Jon Carter
Diagnosing a 'down looker'
Advertisement
Articles in this issue
about 6 years ago
Aspheric, aberration-free IOL leverages technology for performanceabout 6 years ago
Emerging opportunities — and risks — with telehealth in a pandemicabout 6 years ago
Toric stability: A minor change with a major impact for patientsabout 6 years ago
Dropless, hands-free regimen key for patientsabout 6 years ago
Amid pandemic, friendly bugs can help protect the eye from infectionabout 6 years ago
Gene therapy offers hope for choroideremiaabout 6 years ago
Machine-learning algorithms could help predict course of NPDRabout 6 years ago
Thyroid eye disease: Not limited to visual impairmentabout 6 years ago
Beating burnout with camaraderieAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
3
Demodex blepharitis: Diagnosis, treatment response, and recurrence
4
SpyGlass Pharma's BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5